Kevin Furlong
Wyoming State Department of Health(US)
Publications by Year
Research Areas
SARS-CoV-2 and COVID-19 Research, Diabetes, Cardiovascular Risks, and Lipoproteins, Metabolism, Diabetes, and Cancer, Diabetes Treatment and Management, Diabetes Management and Research
Most-Cited Works
- → Neoplastic progression occurs through mutator pathways in hyperplastic polyposis of the colorectum(2000)254 cited
- → Masitinib is a broad coronavirus 3CL inhibitor that blocks replication of SARS-CoV-2(2021)248 cited
- → Circulating ACE2-expressing extracellular vesicles block broad strains of SARS-CoV-2(2022)164 cited
- → Long-term Effects of Metformin on Diabetes Prevention: Identification of Subgroups That Benefited Most in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study(2019)124 cited
- → An immunohistochemical assessment of cellular proliferation markers in head and neck squamous cell cancers(1990)109 cited
- → Regression From Prediabetes to Normal Glucose Regulation and Prevalence of Microvascular Disease in the Diabetes Prevention Program Outcomes Study (DPPOS)(2019)101 cited
- → Effect of Metformin and Lifestyle Interventions on Mortality in the Diabetes Prevention Program and Diabetes Prevention Program Outcomes Study(2021)95 cited
- → The Impact of Physical Activity on the Prevention of Type 2 Diabetes: Evidence and Lessons Learned From the Diabetes Prevention Program, a Long-Standing Clinical Trial Incorporating Subjective and Objective Activity Measures(2020)69 cited
- → Drug repurposing screen identifies masitinib as a 3CLpro inhibitor that blocks replication of SARS-CoV-2 in vitro(2020)42 cited
- → Polymersomes Decorated with the SARS-CoV-2 Spike Protein Receptor-Binding Domain Elicit Robust Humoral and Cellular Immunity(2021)37 cited